Tegoprubart (AT-1501) - (BESTOW)

June 25, 2026: Natera, Inc. (NASDAQ: NTRA) and Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced a strategic partnership to use Natera’s Prospera kidney transplant assessment test as the exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation. Eledon said it has established the regulatory framework for the Phase 3 kidney transplantation program and expects to initiate the trial in late 2026.

The Phase 3 study is planned to enroll ~600 kidney transplant recipients across 100+ transplant centers globally. Prospera will be used for longitudinal surveillance monitoring, using a two-threshold algorithm measuring dd-cfDNA fraction (dd-cfDNA%) and total dd-cfDNA (DQS), to detect early signs of rejection/allograft injury that may prompt further evaluation (including biopsy).

Tegoprubart is described as an investigational anti-CD40L antibody intended to prevent organ rejection and potentially reduce toxicities associated with standard immunosuppressive therapies such as tacrolimus. The companies noted this is the first planned use of Prospera as a longitudinal surveillance tool in a large-scale therapeutic transplantation trial.